Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Internal Medicine Journal · 2025
DOI: 10.1111/imj.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Georgia McCaughan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Advisory Committees, Disease Management, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The survival of newly diagnosed patients with multiple myeloma has improved significantly over the past 20 years with significant therapeutic advances. Despite this, high‐dose chemotherapy followed by autologous stem cell transplantation remains the standard of care in newly diagnosed patients who are considered transplant eligible. Here, we summarise the recommendations of the Medical and Scientific Advisory Group of Myeloma Australia for patients considered suitable for high‐dose chemotherapy and autologous stem cell transplantation as part of the initial therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
- School of Clinical Medicine, UNSW Medicine and Health, Sydney, New South Wales, Australia.
- Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Myeloma Australia, Melbourne, Victoria, Australia.
- Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: P Joy Ho, Dipti Talaulikar
Zitieren
APA
McCaughan, G., Beer, H., Bryant, C., Ho, P. J., King, T., Lee, C., Mollee, P., Prince, H. M., Spencer, A., Talaulikar, D., Vandyke, K., Weber, N., Yong, A., Harrison, S., & Quach, H. (2025). Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.70148
Vancouver
McCaughan G, Beer H, Bryant C, Ho PJ, King T, Lee C, et al. Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal. 2025. doi:10.1111/imj.70148
BibTeX
@article{McCaughan2025,
author = {McCaughan, Georgia and Beer, Hayley and Bryant, Christian and Ho, P Joy and King, Tracy and Lee, Cindy and Mollee, Peter and Prince, H Miles and Spencer, Andrew and Talaulikar, Dipti and Vandyke, Kate and Weber, Nicholas and Yong, Angelina and Harrison, Simon and Quach, Hang},
title = {Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.70148}
}
EUVIMED